Login to Your Account

Venatorx raises $42M to move phase I antibiotic program into pivotal trials

By Cormac Sheridan
Staff Writer

Tuesday, July 25, 2017

DUBLIN – Antibiotics developer Venatorx Pharmaceuticals Inc. raised $42 million in a series B round that will fund a registration trial of its lead program, VNRX-5133, which it has penciled in for the first half of next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription